ReproCELL Incorporated
Tokyo Stock Exchange 4978.T
ReproCELL Incorporated Capital Expenditure for the year ending March 31, 2024: USD -1.27 M
-
ReproCELL Incorporated Capital Expenditure for the year ending March 31, 2023 was USD -1.21 M, a -207.19% change year over year.
-
ReproCELL Incorporated Capital Expenditure for the year ending March 31, 2022 was USD -394.57 K, a 32.01% change year over year.
-
ReproCELL Incorporated Capital Expenditure for the year ending March 31, 2021 was USD -580.33 K, a 55.69% change year over year.
-
ReproCELL Incorporated Capital Expenditure for the year ending March 31, 2020 was USD -1.31 M, a -49.75% change year over year.
| Date | Capital Expenditure | Free Cash Flow | Depreciation And Amortization | Deferred Income Tax |
|---|
Don’t Miss A Beat
| CEO | Dr. Shuji Yokoyama Ph.D. |
| IPO Date | June 26, 2013 |
| Location | Japan |
| Headquarters | MetLife Shin-Yokohama Building |
| Employees | 96 |
| Sector | Healthcare |
| Industries | |
ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
Past 5 years
USD 0.92
USD 0.17
StockViz Staff
February 8, 2025
Any question? Send us an email